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Abstract 
 
Adenosine receptor signaling plays important roles in normal physiology, but is also known 
to modulate the development or progression of several different diseases. The design of 
new, efficient, and safe pharmacological approaches to target the adenosine system may 
have considerable therapeutic potential, but is also associated with many challenges. This 
review summarizes the main challenges of adenosine receptor targeted treatment including 
tolerance, disease stage, cell type-specific effects, caffeine intake, adenosine level 
assessment and receptor distribution in vivo. Moreover, we discuss several potential ways to 
overcome these obstacles (i.e., the use of partial agonists, indirect receptor targeting, 
allosteric enhancers, prodrugs, non-receptor-mediated effects, neoreceptors, conditional 
knockouts). It is important to address these concerns during development of new and 
successful therapeutic approaches targeting the adenosine system.  
 
Key Words: Adenosine; adenosine receptor; drug target, drug discovery; pharmacology; 
disease 
 
Abbreviations: T1D, type 1 diabetes; T2D, type 2 diabetes; A1AR, A1 adenosine receptor; 
A2AAR, A2A adenosine receptor; A2BAR, A2B adenosine receptor; A3AR, A3 adenosine receptor   
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1. Introduction 
Since adenosine receptor-mediated signaling plays a role in modulating the progression of 
various pathological disorders, the creation of efficient and safe pharmacological ligands has 
considerable therapeutic potential, but is fraught with difficulty (Chen et al 2013). Efforts in 
medicinal and organic chemistry have been fruitful and numerous adenosine analogues with 
high affinity and selectivity have been generated (Fredholm et al., 2001; Fredholm et al., 
2011). Therefore, the lack of selective ligands is not the major problem. The biggest 
challenge to overcome is the widespread expression of adenosine receptors and the 
redundancy of adenosine signaling.  
 
2. Challenges associated with pharmacological targeting of adenosine signaling  
 
2.1. Widespread distribution of adenosine receptors  
Adenosine receptors are present on most cells. This means that a given type of adenosine 
receptor is going to be present not only on the target cell(s) involved in a disease process, 
but also on cells that are involved in very diverse physiological processes. This problem is 
accentuated with promiscuous agonists, which activate all receptors, than with antagonists 
selective to cells with substantial ongoing activation (Chen et al., 2013). 
 
2.2. Tolerance  
Tolerance can develop after repeated or chronic ligand exposure  desensitizing receptor 
activation or reducing the signaling response of the targeted receptor over time. This can be 
due to reduced receptor expression, receptor internalization, or other mechanisms reducing 
the end effect of a specific dose of ligand. Tolerance has been reported for A1AR agonists 
and A2AAR agonists (Burgueno et al., 2003; de Mendonca et al., 2000; Jacobson et al., 1996), 
but it seems likely to occur also for A2B and A3 agonists. Use of receptor antagonists 
decreases the risk of tolerance, since this would require that the endogenous agonist 
occupies enough receptors as to cause desensitization. Indeed, even for A2AAR which is very 
abundant in the basal ganglia, constantly occupied antagonists do not cause tolerance, 
making such drugs promising as therapeutic agents (Halldner et al., 2000; Pinna et al., 2001). 
 
2.3. Developmental or disease stage  
Many times the blockade of a specific adenosine receptor has almost opposite effects 
depending on the developmental stage of the tested animals. This has already been 
reported in relation to the role of A1AR or A2AAR in brain injury (Aden et al., 2003; Chen et 
al., 1999; Cunha, 2005; Turner et al., 2003) and in relation to metabolic abnormalities, 
contradictory findings related to the A1 and A2B receptors could be attributed to the different 
developmental stages (Csoka et al., 2014; Figler et al., 2011; Johansson et al., 2007; Peleli et 
al., 2015; Yang et al., 2015). Moreover, in various disease models both protective and 
detrimental effects of adenosine receptor activation have been observed depending on the 
stage of the disorder confirming the high complexity of the adenosine receptor-mediated 
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signaling (Chen et al., 2013). This also has implications in the conclusions one can draw from 
single adenosine receptor knockout mice on the usefulness of adenosine receptor 
antagonists.  
 
2.4. Distinct effects on different cell types 
The distinct effects of adenosine on different cell types become evident in the case of 
metabolic disorders. For example, diabetes mellitus involve the participation of many 
different organs such as pancreas, liver, skeletal muscle, and adipose tissue. Moreover, low-
grade inflammation together with oxidative stress has been shown to be important in the 
progression of metabolic abnormalities. Considering that all the adenosine receptors are 
expressed on the different metabolic organs and various immune cells it becomes evident 
that the administration of a molecule that targets a specific adenosine receptor will have 
many and potentially opposing outcomes. For example, as nicely reviewed by Eisenstein et 
al. (Eisenstein et al., 2015) there are many opposing findings regarding the role of A2BAR in 
metabolic pathologies since this receptor simultaneously and differently affects  acute and 
chronic inflammation (macrophages), adipogenesis (adipose tissue), insulin release 
(pancreas) and gluconeogenesis as well as glycogenolysis (liver). Additionally, A2AAR 
receptors seem essential in developing or maintaining endothelial dysfunction in the 
fetoplacental vasculature in diseases of pregnancy such as gestational diabetes mellitus or 
preeclampsia (Salsoso et al., 2015; Sobrevia et al., 2016). However, the A1AR is required for 
the effect of insulin correcting the gestational diabetes mellitus-enhanced L-arginine 
transport in this vascular bed (Guzman-Gutierrez et al., 2016).    
 
2.5. Widespread use of caffeine 
Although often underestimated, a very large part of the adult population consumes coffee 
on a daily basis. Two cups of coffee leads to an almost 50% blockade of the A1AR and A2AAR 
(Fredholm et al., 1999). Therefore, any new drug on the market that inhibits adenosine 
receptors should be able to exert a larger and more obvious effect compared to the one 
already existing from the low-cost caffeine. In agreement to this concept, any new clinical 
trial affecting adenosine receptors must carefully calculate the caffeine intake of the study’s 
participants and interpret any results with caution. 
 
2.6. Measuring adenosine levels or the number-distribution of adenosine receptors in vivo 
The reliable measurement of adenosine and its receptors on a specific tissue in vivo is crucial 
for understanding its biology and pharmacology. However, adenosine’s concentration varies 
a lot over time and current methodological approaches destroy some cells locally, potentially 
leading to higher false positive measurements (Chen et al., 2013). Interestingly, the 
adenosine plasma concentration in the human umbilical vein at birth is higher in gestational 
diabetes mellitus compared with normal pregnancies (Westermeier et al., 2015), and 
maternal plasma concentration of this nucleoside is elevated at early stages of pregnancy in 
women that later develop preeclampsia (Escudero and Sobrevia, 2008; Espinoza et al., 
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2011). Moreover, we are still lacking knowledge of how the different receptors are 
distributed in patients with various diseases. The latter problem could be potentially solved 
by taking advantage of the newest in vivo imaging methods already in practice with A2AAR 
ligands in patients with Parkinson’s disease (Mishina et al., 2011; Ramlackhansingh et al., 
2011). Therefore, the advancement in analytical methods for assessing adenosine and its 
receptors would be of great aid for the use of adenosine receptor drugs in therapy only 
when adenosine receptors alterations are observed as an example of personalized medicine. 
 
3. Potential approaches to target adenosine receptor signaling  
There are several potential ways to overcome some of the abovementioned obstacles, 
including: 
 
3.1. Partial agonists 
Partial agonists are drugs that bind to and activate a receptor, but they have only partial 
efficacy compared to the full agonist. In practice this means that a partial agonist acts 
predominantly as an antagonist when there is substantial endogenous signaling of the 
targeted receptor (Lambert, 2004). Indeed, many commonly used “antagonists” are in fact 
partial agonists. A high expression levels of a receptor are positively correlated to the 
receptor reserve phenomenon across different tissues (Kenakin, 2009). Receptor reserve, 
which means that stimulation of only a fraction of the receptors is sufficient to elicit the 
maximum response in case of a full agonist, is very sensitive to an agonist’s intrinsic efficacy 
and therefore.  This implies that a full agonist can exert strong effects even at tissues where 
there is relatively low expression of a receptor. This simultaneous action of a full agonist on 
many target tissues could lead potentially to many side effects. However, this is not the case 
when a partial agonist is administrated and therefore many of the side effects on other 
tissues are avoided. For example, the adipocytes highly express A1AR and therefore partial 
A1AR agonists can more selectively target those receptors instead of others (Dhalla et al., 
2003). 
 
3.2. Indirect receptor targeting 
An alternative approach that could lead to less side effects is to increase the local 
endogenous adenosine concentration and therefore activate the surrounding adenosine 
receptors. This approach could provide some degree of tissue specificity, but more studies 
are warranted in order to establish this hypothesis. Drugs that could be used include 
adenosine deaminase inhibitors (e.g. deoxycoformycin) and adenosine uptake inhibitors, 
including dipyridamole and ticagrelor. Both deoxycoformycin and ticagrelor have already 
been used in clinical trials with T1D or acute coronary syndrome patients, showing some 
beneficial effects related to renovascular diabetic complications, e.g. reduced albuminuria 
and platelet activation (Aizawa et al., 1990; Bonello et al., 2014; Laine et al., 2014). In 
addition to diabetes and cardiovascular disease, alternative strategies for increasing locally 
adenosine levels are tested in epilepsy. In particular, adenosine kinase (ADK) seems to be a 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 7
key regulator of adenosine’s clearance in the brain and over-activation of ADK results in 
adenosine deficiency and seizures (Boison, 2013). Therefore, efforts have been made in 
targeting and inactivating ADK in specific brain areas, which could potentially reduce the 
frequency of epileptic episodes. For example, gene therapy directed to ADK through an 
antisense oligonucleotide is being explored as a means of conserving adenosine by reducing 
ADK expression in animal models of epilepsy (Boison, 2010). Promisingly, adenosine has also 
been delivered directly to the brain ventricles of epileptic rats, thereby reducing DNA 
methylation and slowing disease progression (Borea et al., 2016). 
 
3.3. Allosteric enhancers 
Allosteric enhancers are molecules that bind to the adenosine receptors on a different site 
compared to the agonist, and stabilize the tertiary complex between agonist, receptor and 
the G-protein. This action can for example stabilize the binding of endogenous adenosine 
and enhance its effects when its concentration increases locally. This magnifies the effects of 
adenosine in an event-responsive and temporally specific manner, thus minimizing the side 
effects. So far, allosteric enhancers have successfully been used for the A1AR and A3AR, 
enhancing adenosine’s anti-lipolytic and anti-ischemic action, respectively (Goblyos and 
Ijzerman, 2011). 
 
3.4. Prodrugs  
Another approach for a more specific tissue targeting of an adenosine receptor ligand is the 
administration of a molecule in an inactive form (i.e. prodrug), which is subsequently 
activated at the desired tissue by a locally expressed enzyme. To this end, prodrugs have 
been generated, acting as A2AAR agonist after selective cleavage by the enzyme ecto-5'-
nucleotidase or CD73 in inflamed tissues (Flogel et al., 2012). 
 
3.5. Multiple targets of adenosine signaling (not only at the receptor level) 
The use of multi-target drugs that act not only at the receptor level, but also influence the 
biosynthesis or metabolism of adenosine, can potentially enhance its effects since they act 
simultaneously on many different levels. For example drugs have been synthesized that 
combine a dual action of an A2AAR agonist together with adenosine transporter or 
monoamine oxidase B inhibition (Chen et al., 2002; Huang et al., 2011). These drugs have 
demonstrated improved efficacy in neurodegenerative disorders such as Parkinson’s or 
Huntington’s disease. 
 
3.6. Design of neoceptors 
The term neoceptor refers to reengineered adenosine receptors that recognize selectively 
uniquely modified ligands (neoligands), which are unable to bind to and activate the 
endogenous receptors. This approach gives spatial and temporal specificity since the 
neoceptor can be selectively targeted to a specific tissue and the neoligand can be 
administrated only when needed (Jacobson et al., 2007). So far, neoceptors and respective 
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ligands have been designed for A1AR, A2AAR and A3AR (Gao et al., 2006; Jacobson et al., 
2001; Jacobson et al., 2005; Palaniappan et al., 2007). This technology is undoubtedly 
promising, but many more in vivo studies are warranted in order to evaluate its practical 
efficacy. Potential difficulties could result to the use of genetic targeting techniques in man. 
 
3.7. Use of conditional knockouts (Cre-Lox recombination) and shRNA approaches 
These approaches would provide us with a better understanding of the spatial and temporal 
changes of the adenosine-mediated receptor signaling and would hopefully allow us to 
synthesize more efficient and selective drugs that target the adenosine receptors. So far 
most of the studies have used global knockouts or adenosine receptor ligands that could act 
simultaneously on many different target tissues and the results have often been conflicting. 
Therefore, the use-creation of conditional knockout mice or shRNA approaches for selective 
gene silencing is imperative. So far conditional knockouts for the A2AAR and A1AR for specific 
brain areas have been created (Lazarus et al., 2011; Scammell et al., 2003).  
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4. Conclusions 
There are many ongoing or already completed phase I-III clinical trials with adenosine 
receptor ligands for various diseases, but for all the above mentioned reasons few of them 
may reach the clinic. So far, the clinical applications of adenosine itself, A1AR, A2AAR and 
A3AR agonists, caffeine, A1AR and A2AAR antagonists have been tested against several 
pathologies such as liver ischemia and liver cancer, treatment after stenting, blood flow in 
T1D, wound healing after foot ulcers in T1D and T2D, psoriasis, rheumatoid arthritis, acute 
heart failure and Parkinson’s disease (Avni et al., 2010; Chen et al., 2013; Fernandez et al., 
2010; Fishman et al., 2012; Massie et al., 2010; Pinna, 2009; Powers et al., 2008; Schmidt et 
al., 2006, 2007; Silverman et al., 2008). Some of the findings from these clinical trials are 
promising, but in many cases the tested drugs seem to be ineffective indicating the 
importance of overcoming the above mentioned obstacles. For example, there are several 
studies showing that non-selective adenosine receptor inhibitors improve hypoglycemia 
unawareness in T1D or insulin secretion in T2D (Arias et al., 2001; de Galan et al., 2002). 
Moreover, pharmacological agents that lead to higher extracellular concentration of 
adenosine decrease albuminuria in diabetic patients (Aizawa et al., 1990). However, so far 
there are no data from large-scale clinical trials or from more selective adenosine receptor 
ligands. In addition, a large-scale trial where adenosine was administrated as an adjunct to 
reperfusion in the treatment of acute myocardial infarction concluded that adenosine did 
not prevent the development of heart failure but was able to significantly reduce the infract 
size (Ross et al., 2005). Parkinson’s disease is also another example of pathology where 
targeting of the adenosine receptors seem to have a therapeutic potential (Lopes et al., 
2011). Despite encouraging findings of the administration of A2AAR antagonists in rodent and 
primate models of Parkinson’s disease, these effects have proven difficult to demonstrate on 
a consistent basis in humans (Morelli et al., 2009). Therefore, the design of more targeted 
proper clinical studies is a necessity to establish the therapeutic value. According to the 
current bibliographic literature, and everything mentioned above,  more selective targeting 
of A1AR, A2AAR, A2BAR and A3AR would be a very promising approach provided that issues, 
such as age of the individuals, main targeted tissue, stage and type of the disease, are 
carefully taken into consideration. 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10
Acknowledgements 
This work was supported by grants from the Swedish Heart and Lung Foundation (Dnr: 
20110589 & 20140448), the Swedish Research Council (Dnr: 2016-01381), Fondo Nacional 
de Desarrollo Científico y Tecnológico (FONDECYT 1150377; Chile), the Bodossaki Foundation 
(Dnr 2012-2015; Athens, Greece) and by KID-funding from the Karolinska Institutet (Dnr 
2415/2012-225 and Dnr 2-3707/2013). 
 
 
Conflict(s) of Interest 
None 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11
References 
Aden, U., Halldner, L., Lagercrantz, H., Dalmau, I., Ledent, C., Fredholm, B.B., 2003. 
Aggravated brain damage after hypoxic ischemia in immature adenosine A2A knockout mice. 
Stroke 34 (3), 739-744. 
Aizawa, T., Suzuki, S., Asawa, T., Komatsu, M., Shigematsu, S., Okada, N., Katakura, M., 
Hiramatsu, K., Shinoda, T., Hashizume, K., et al., 1990. Dipyridamole reduces urinary albumin 
excretion in diabetic patients with normo- or microalbuminuria. Clin Nephrol 33 (3), 130-
135. 
Arias, A.M., Bisschop, P.H., Ackermans, M.T., Nijpels, G., Endert, E., Romijn, J.A., Sauerwein, 
H.P., 2001. Aminophylline stimulates insulin secretion in patients with type 2 diabetes 
mellitus. Metabolism 50 (9), 1030-1035. 
Avni, I., Garzozi, H.J., Barequet, I.S., Segev, F., Varssano, D., Sartani, G., Chetrit, N., Bakshi, E., 
Zadok, D., Tomkins, O., Litvin, G., Jacobson, K.A., Fishman, S., Harpaz, Z., Farbstein, M., 
Yehuda, S.B., Silverman, M.H., Kerns, W.D., Bristol, D.R., Cohn, I., Fishman, P., 2010. 
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical 
trial. Ophthalmology 117 (7), 1287-1293. 
Boison, D., 2010. Inhibitory RNA in epilepsy: research tools and therapeutic perspectives. 
Epilepsia 51 (9), 1659-1668. 
Boison, D., 2013. Role of adenosine in status epilepticus: a potential new target? Epilepsia 54 
Suppl 6, 20-22. 
Bonello, L., Laine, M., Kipson, N., Mancini, J., Helal, O., Fromonot, J., Gariboldi, V., Condo, J., 
Thuny, F., Frere, C., Camoin-Jau, L., Paganelli, F., Dignat-George, F., Guieu, R., 2014. 
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary 
syndrome. J Am Coll Cardiol 63 (9), 872-877. 
Borea, P.A., Gessi, S., Merighi, S., Varani, K., 2016. Adenosine as a Multi-Signalling Guardian 
Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects? Trends 
Pharmacol Sci 37 (6), 419-434. 
Burgueno, J., Blake, D.J., Benson, M.A., Tinsley, C.L., Esapa, C.T., Canela, E.I., Penela, P., 
Mallol, J., Mayor, F., Jr., Lluis, C., Franco, R., Ciruela, F., 2003. The adenosine A2A receptor 
interacts with the actin-binding protein alpha-actinin. J Biol Chem 278 (39), 37545-37552. 
Chen, J.F., Eltzschig, H.K., Fredholm, B.B., 2013. Adenosine receptors as drug targets--what 
are the challenges? Nat Rev Drug Discov 12 (4), 265-286. 
Chen, J.F., Huang, Z., Ma, J., Zhu, J., Moratalla, R., Standaert, D., Moskowitz, M.A., Fink, J.S., 
Schwarzschild, M.A., 1999. A(2A) adenosine receptor deficiency attenuates brain injury 
induced by transient focal ischemia in mice. J Neurosci 19 (21), 9192-9200. 
Chen, J.F., Steyn, S., Staal, R., Petzer, J.P., Xu, K., Van Der Schyf, C.J., Castagnoli, K., Sonsalla, 
P.K., Castagnoli, N., Jr., Schwarzschild, M.A., 2002. 8-(3-Chlorostyryl)caffeine may attenuate 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 12
MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor 
antagonism. J Biol Chem 277 (39), 36040-36044. 
Csoka, B., Koscso, B., Toro, G., Kokai, E., Virag, L., Nemeth, Z.H., Pacher, P., Bai, P., Hasko, G., 
2014. A2B adenosine receptors prevent insulin resistance by inhibiting adipose tissue 
inflammation via maintaining alternative macrophage activation. Diabetes 63 (3), 850-866. 
Cunha, R.A., 2005. Neuroprotection by adenosine in the brain: From A(1) receptor activation 
to A (2A) receptor blockade. Purinergic Signal 1 (2), 111-134. 
de Galan, B.E., Tack, C.J., Lenders, J.W., Pasman, J.W., Elving, L.D., Russel, F.G., Lutterman, 
J.A., Smits, P., 2002. Theophylline improves hypoglycemia unawareness in type 1 diabetes. 
Diabetes 51 (3), 790-796. 
de Mendonca, A., Sebastiao, A.M., Ribeiro, J.A., 2000. Adenosine: does it have a 
neuroprotective role after all? Brain Res Brain Res Rev 33 (2-3), 258-274. 
Dhalla, A.K., Shryock, J.C., Shreeniwas, R., Belardinelli, L., 2003. Pharmacology and 
therapeutic applications of A1 adenosine receptor ligands. Curr Top Med Chem 3 (4), 369-
385. 
Eisenstein, A., Patterson, S., Ravid, K., 2015. The Many Faces of the A2b Adenosine Receptor 
in Cardiovascular and Metabolic Diseases. J Cell Physiol 230 (12), 2891-2897. 
Escudero, C., Sobrevia, L., 2008. A hypothesis for preeclampsia: adenosine and inducible 
nitric oxide synthase in human placental microvascular endothelium. Placenta 29 (6), 469-
483. 
Espinoza, J., Espinoza, A.F., Power, G.G., 2011. High fetal plasma adenosine concentration: a 
role for the fetus in preeclampsia? American journal of obstetrics and gynecology 205 (5), 
485 e424-487. 
Fernandez, H.H., Greeley, D.R., Zweig, R.M., Wojcieszek, J., Mori, A., Sussman, N.M., Group, 
U.S.S., 2010. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 
trial. Parkinsonism Relat Disord 16 (1), 16-20. 
Figler, R.A., Wang, G., Srinivasan, S., Jung, D.Y., Zhang, Z., Pankow, J.S., Ravid, K., Fredholm, 
B., Hedrick, C.C., Rich, S.S., Kim, J.K., LaNoue, K.F., Linden, J., 2011. Links between insulin 
resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. 
Diabetes 60 (2), 669-679. 
Fishman, P., Bar-Yehuda, S., Liang, B.T., Jacobson, K.A., 2012. Pharmacological and 
therapeutic effects of A3 adenosine receptor agonists. Drug discovery today 17 (7-8), 359-
366. 
Flogel, U., Burghoff, S., van Lent, P.L., Temme, S., Galbarz, L., Ding, Z., El-Tayeb, A., Huels, S., 
Bonner, F., Borg, N., Jacoby, C., Muller, C.E., van den Berg, W.B., Schrader, J., 2012. Selective 
activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 13
suppresses joint inflammation in experimental rheumatoid arthritis. Sci Transl Med 4 (146), 
146ra108. 
Fredholm, B.B., AP, I.J., Jacobson, K.A., Klotz, K.N., Linden, J., 2001. International Union of 
Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 
53 (4), 527-552. 
Fredholm, B.B., AP, I.J., Jacobson, K.A., Linden, J., Muller, C.E., 2011. International Union of 
Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine 
receptors--an update. Pharmacol Rev 63 (1), 1-34. 
Fredholm, B.B., Battig, K., Holmen, J., Nehlig, A., Zvartau, E.E., 1999. Actions of caffeine in 
the brain with special reference to factors that contribute to its widespread use. Pharmacol 
Rev 51 (1), 83-133. 
Gao, Z.G., Duong, H.T., Sonina, T., Kim, S.K., Van Rompaey, P., Van Calenbergh, S., 
Mamedova, L., Kim, H.O., Kim, M.J., Kim, A.Y., Liang, B.T., Jeong, L.S., Jacobson, K.A., 2006. 
Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored 
nucleoside agonists. J Med Chem 49 (9), 2689-2702. 
Goblyos, A., Ijzerman, A.P., 2011. Allosteric modulation of adenosine receptors. Biochim 
Biophys Acta 1808 (5), 1309-1318. 
Guzman-Gutierrez, E., Armella, A., Toledo, F., Pardo, F., Leiva, A., Sobrevia, L., 2016. Insulin 
requires A1 adenosine receptors expression to reverse gestational diabetes-increased L-
arginine transport in human umbilical vein endothelium. Purinergic signalling 12 (1), 175-
190. 
Halldner, L., Lozza, G., Lindstrom, K., Fredholm, B.B., 2000. Lack of tolerance to motor 
stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur J Pharmacol 406 
(3), 345-354. 
Huang, N.K., Lin, J.H., Lin, J.T., Lin, C.I., Liu, E.M., Lin, C.J., Chen, W.P., Shen, Y.C., Chen, H.M., 
Chen, J.B., Lai, H.L., Yang, C.W., Chiang, M.C., Wu, Y.S., Chang, C., Chen, J.F., Fang, J.M., Lin, 
Y.L., Chern, Y., 2011. A new drug design targeting the adenosinergic system for Huntington's 
disease. PLoS One 6 (6), e20934. 
Jacobson, K.A., Gao, Z.G., Chen, A., Barak, D., Kim, S.A., Lee, K., Link, A., Rompaey, P.V., van 
Calenbergh, S., Liang, B.T., 2001. Neoceptor concept based on molecular complementarity in 
GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-
modified nucleosides. J Med Chem 44 (24), 4125-4136. 
Jacobson, K.A., Gao, Z.G., Liang, B.T., 2007. Neoceptors: reengineering GPCRs to recognize 
tailored ligands. Trends Pharmacol Sci 28 (3), 111-116. 
Jacobson, K.A., Ohno, M., Duong, H.T., Kim, S.K., Tchilibon, S., Cesnek, M., Holy, A., Gao, Z.G., 
2005. A neoceptor approach to unraveling microscopic interactions between the human A2A 
adenosine receptor and its agonists. Chem Biol 12 (2), 237-247. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14
Jacobson, K.A., von Lubitz, D.K., Daly, J.W., Fredholm, B.B., 1996. Adenosine receptor ligands: 
differences with acute versus chronic treatment. Trends in pharmacological sciences 17 (3), 
108-113. 
Johansson, S.M., Salehi, A., Sandstrom, M.E., Westerblad, H., Lundquist, I., Carlsson, P.O., 
Fredholm, B.B., Katz, A., 2007. A1 receptor deficiency causes increased insulin and glucagon 
secretion in mice. Biochem Pharmacol 74 (11), 1628-1635. 
Kenakin, T., 2009. A pharmacology primer: theory, application and methods, 3rd ed. Elsevier 
Academic Press. 
Laine, M., Frere, C., Toesca, R., Berbis, J., Barnay, P., Pansieri, M., Michelet, P., Bessereau, J., 
Camilleri, E., Ronsin, O., Helal, O., Paganelli, F., Dignat-George, F., Bonello, L., 2014. 
Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A 
pharmacodynamic randomised study. Thromb Haemost 111 (2), 273-278. 
Lambert, D.G., 2004. Drugs and receptors. Contin Educ Anaesth Crit Care Pain 4 (6), 181-184. 
Lazarus, M., Shen, H.Y., Cherasse, Y., Qu, W.M., Huang, Z.L., Bass, C.E., Winsky-Sommerer, R., 
Semba, K., Fredholm, B.B., Boison, D., Hayaishi, O., Urade, Y., Chen, J.F., 2011. Arousal effect 
of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J 
Neurosci 31 (27), 10067-10075. 
Lopes, L.V., Sebastiao, A.M., Ribeiro, J.A., 2011. Adenosine and related drugs in brain 
diseases: present and future in clinical trials. Current topics in medicinal chemistry 11 (8), 
1087-1101. 
Massie, B.M., O'Connor, C.M., Metra, M., Ponikowski, P., Teerlink, J.R., Cotter, G., 
Weatherley, B.D., Cleland, J.G., Givertz, M.M., Voors, A., DeLucca, P., Mansoor, G.A., Salerno, 
C.M., Bloomfield, D.M., Dittrich, H.C., Investigators, P., Committees, 2010. Rolofylline, an 
adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363 (15), 1419-1428. 
Mishina, M., Ishiwata, K., Naganawa, M., Kimura, Y., Kitamura, S., Suzuki, M., Hashimoto, M., 
Ishibashi, K., Oda, K., Sakata, M., Hamamoto, M., Kobayashi, S., Katayama, Y., Ishii, K., 2011. 
Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease 
patients. PLoS One 6 (2), e17338. 
Morelli, M., Carta, A.R., Jenner, P., 2009. Adenosine A2A receptors and Parkinson's disease. 
Handb Exp Pharmacol (193), 589-615. 
Palaniappan, K.K., Gao, Z.G., Ivanov, A.A., Greaves, R., Adachi, H., Besada, P., Kim, H.O., Kim, 
A.Y., Choe, S.A., Jeong, L.S., Jacobson, K.A., 2007. Probing the binding site of the A1 
adenosine receptor reengineered for orthogonal recognition by tailored nucleosides. 
Biochemistry 46 (25), 7437-7448. 
Peleli, M., Hezel, M., Zollbrecht, C., Persson, A.E., Lundberg, J.O., Weitzberg, E., Fredholm, 
B.B., Carlstrom, M., 2015. In adenosine A2B knockouts acute treatment with inorganic 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 15
nitrate improves glucose disposal, oxidative stress, and AMPK signaling in the liver. Front 
Physiol 6, 222. 
Pinna, A., 2009. Novel investigational adenosine A2A receptor antagonists for Parkinson's 
disease. Expert Opin Investig Drugs 18 (11), 1619-1631. 
Pinna, A., Fenu, S., Morelli, M., 2001. Motor stimulant effects of the adenosine A2A receptor 
antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-
hydroxydopamine-lesioned rats. Synapse 39 (3), 233-238. 
Powers, K.M., Kay, D.M., Factor, S.A., Zabetian, C.P., Higgins, D.S., Samii, A., Nutt, J.G., 
Griffith, A., Leis, B., Roberts, J.W., Martinez, E.D., Montimurro, J.S., Checkoway, H., Payami, 
H., 2008. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov 
Disord 23 (1), 88-95. 
Ramlackhansingh, A.F., Bose, S.K., Ahmed, I., Turkheimer, F.E., Pavese, N., Brooks, D.J., 2011. 
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson 
disease. Neurology 76 (21), 1811-1816. 
Ross, A.M., Gibbons, R.J., Stone, G.W., Kloner, R.A., Alexander, R.W., Investigators, A.-I., 
2005. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an 
adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am 
Coll Cardiol 45 (11), 1775-1780. 
Salsoso, R., Guzman-Gutierrez, E., Saez, T., Bugueno, K., Ramirez, M.A., Farias, M., Pardo, F., 
Leiva, A., Sanhueza, C., Mate, A., Vazquez, C., Sobrevia, L., 2015. Insulin restores L-arginine 
transport requiring adenosine receptors activation in umbilical vein endothelium from late-
onset preeclampsia. Placenta 36 (3), 287-296. 
Scammell, T.E., Arrigoni, E., Thompson, M.A., Ronan, P.J., Saper, C.B., Greene, R.W., 2003. 
Focal deletion of the adenosine A1 receptor in adult mice using an adeno-associated viral 
vector. J Neurosci 23 (13), 5762-5770. 
Schmidt, B., Roberts, R.S., Davis, P., Doyle, L.W., Barrington, K.J., Ohlsson, A., Solimano, A., 
Tin, W., Caffeine for Apnea of Prematurity Trial, G., 2006. Caffeine therapy for apnea of 
prematurity. N Engl J Med 354 (20), 2112-2121. 
Schmidt, B., Roberts, R.S., Davis, P., Doyle, L.W., Barrington, K.J., Ohlsson, A., Solimano, A., 
Tin, W., Caffeine for Apnea of Prematurity Trial, G., 2007. Long-term effects of caffeine 
therapy for apnea of prematurity. N Engl J Med 357 (19), 1893-1902. 
Silverman, M.H., Strand, V., Markovits, D., Nahir, M., Reitblat, T., Molad, Y., Rosner, I., 
Rozenbaum, M., Mader, R., Adawi, M., Caspi, D., Tishler, M., Langevitz, P., Rubinow, A., 
Friedman, J., Green, L., Tanay, A., Ochaion, A., Cohen, S., Kerns, W.D., Cohn, I., Fishman-
Furman, S., Farbstein, M., Yehuda, S.B., Fishman, P., 2008. Clinical evidence for utilization of 
the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II 
clinical trial. J Rheumatol 35 (1), 41-48. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 16
Sobrevia, L., Salsoso, R., Fuenzalida, B., Barros, E., Toledo, L., Silva, L., Pizarro, C., Subiabre, 
M., Villalobos, R., Araos, J., Toledo, F., Gonzalez, M., Gutierrez, J., Farias, M., Chiarello, D.I., 
Pardo, F., Leiva, A., 2016. Insulin Is a Key Modulator of Fetoplacental Endothelium Metabolic 
Disturbances in Gestational Diabetes Mellitus. Frontiers in physiology 7, 119. 
Turner, C.P., Seli, M., Ment, L., Stewart, W., Yan, H., Johansson, B., Fredholm, B.B., 
Blackburn, M., Rivkees, S.A., 2003. A1 adenosine receptors mediate hypoxia-induced 
ventriculomegaly. Proc Natl Acad Sci U S A 100 (20), 11718-11722. 
Westermeier, F., Salomon, C., Farias, M., Arroyo, P., Fuenzalida, B., Saez, T., Salsoso, R., 
Sanhueza, C., Guzman-Gutierrez, E., Pardo, F., Leiva, A., Sobrevia, L., 2015. Insulin requires 
normal expression and signaling of insulin receptor A to reverse gestational diabetes-
reduced adenosine transport in human umbilical vein endothelium. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology 29 (1), 37-49. 
Yang, T., Gao, X., Sandberg, M., Zollbrecht, C., Zhang, X.M., Hezel, M., Liu, M., Peleli, M., Lai, 
E.Y., Harris, R.A., Persson, A.E., Fredholm, B.B., Jansson, L., Carlstrom, M., 2015. Abrogation 
of adenosine A1 receptor signalling improves metabolic regulation in mice by modulating 
oxidative stress and inflammatory responses. Diabetologia 58 (7), 1610-1620. 
 
